PSMA Drug Conjugates With Cleavable Linkers for Targeted Payload Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate cancer, such as androgen deprivation therapy, become ineffective as the disease progresses to a castration-resistant phenotype, and there is a need for targeted drug conjugates that can selectively localize at the site of prostate cancer due to PSMA overexpression.
Innovation Solution
Conjugates of a small-molecule PSMA binder with a cytotoxic agent, comprising a PSMA binding moiety, a linker, and a cytotoxic agent, designed to form a stable complex with PSMA and release the cytotoxic payload efficiently at the tumor site.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If androgen deprivation therapy is used to treat prostate cancer, then initial control of metastatic disease is achieved, but the treatment becomes ineffective when the disease progresses to castration-resistant phenotype
Solution Approach 1:
The patent changes the therapeutic approach from hormonal manipulation to targeted cytotoxic delivery by developing PSMA-specific small molecule-drug conjugates. This parameter change in treatment mechanism allows effective targeting of castration-resistant prostate cancer cells that have developed resistance to androgen deprivation therapy.
2Speed
If small molecule ligands are used for targeting applications, then rapid and efficient tumour penetration and lower immunogenicity are achieved, but the challenge of stable conjugate formation and controlled payload release remains
Solution Approach 1:
The patent segments the conjugate into distinct functional modules: a PSMA-targeting small molecule ligand, a cleavable linker (such as Val-Cit), and a cytotoxic payload. This segmentation allows the small ligand to maintain its rapid tumour penetration capability while the engineered linker provides controlled stability in circulation and targeted release at the tumor site through enzymatic cleavage.
Solution Approach 2:
The patent introduces a cleavable linker as an intermediary component between the small molecule ligand and the cytotoxic payload. This intermediary (such as Val-Cit sequence) remains stable during circulation but is specifically cleaved by cathepsin B in the tumor microenvironment, thereby mediating both stable conjugate formation and controlled payload release.
3Manufacturing precision
If targeted drug conjugates are designed to selectively localize at the site of disease, then improved tumor-to-prostate uptake ratio is achieved, but the complexity of linker design and manufacturing increases
Solution Approach 1:
The patent applies local quality by designing the conjugate with site-specific enzymatic cleavage capability. The cleavable linker (Val-Cit) is engineered to be specifically recognized and cleaved by cathepsin B, which is overexpressed in prostate cancer cells. This provides localized activation of the cytotoxic payload precisely at the tumor site while maintaining simplicity in overall conjugate design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugates demonstrate improved tumor-to-prostate uptake ratio, potent anti-tumor effect, and lower toxicity, with enhanced efficacy and a higher therapeutic index compared to prior art.
Implementation Method 1
The conjugates demonstrate improved tumor-to-prostate uptake ratio, potent anti-tumor effect, and lower toxicity, with enhanced efficacy and a higher therapeutic index compared to prior art
Implementation Method 2
WO2022/108992 discloses SMDCs with a PSMA targeting moiety, and a cleavable linker which is cathepsin cleavable, comprising, for example, Val-Cit
Data Source
AI summary
A conjugate of Formula I or a pharmaceutically acceptable salt thereof, wherein: PB is a PSMA binding moiety which has a molecular weight of below 1000 Da; L1 is a linker covalently attaching PB to Gly-Pro, said linker being a saturated or a partially or fully unsaturated framework comprising C and H atoms and at least one heteroatom, wherein said framework has end points of attachment ‘a’ and ‘b’ and a length between 6 and 30 atoms (via the shortest path between PB and Gly-Pro) between ‘a’ and ‘b’; wherein said framework may include one or more straight and/or branched chains and/or rings and is optionally substituted on any available C atom(s) by one or more F; L2 is a either a single bond or a self-immolative linker; and Drug is a cytotoxic agent linked to Gly-Pro.